Information Provided By: 
Fly News Breaks for December 9, 2019
XNCR
Dec 9, 2019 | 11:24 EDT
Xencor's poster presentation with updated data for XmAb13676 shows improving response rates with increasing dose escalation and a manageable safety profile, Mizuho analyst Mara Goldstein tells investors in a research note. The analyst believes a profile of XmAb13676 is emerging with efficacy and safety largely consistent with other bispecifics in the space. Citing "improving clarity" on a path forward, Goldstein maintains a Buy rating on Xencor shares with a $52 price target.
News For XNCR From the Last 2 Days
There are no results for your query XNCR
